Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Marriott International Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Marriott International Inc trades at $377.7 (market cap $99.18B). The key difference: Marriott International Inc is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Marriott International Inc pays a 0.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MAR | |
|---|---|---|
Market Cap | $39.89B | $99.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $402.54 |
52-Week Low | $278.09 | $255.35 |
Enterprise Value | $38.15B | $116.13B |
Dividend Yield | — | 0.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Marriott International (MAR) trades at $376.11, up 0.98% today, with a bearish technical signal and a consensus price target of $386.42. Recent earnings show mixed results, with Q1 2026 beating expectations but Q4 2025 missing. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Key developments include the launch of Ask Bonvoy AI and reaching 10,000 properties globally, though hotel owners are pushing back on loyalty program terms.
Outlook is cautiously optimistic with upside to the consensus target, supported by solid fundamentals and strategic initiatives. Risks include rising debt-to-asset ratio (58.83% in 2025), competitive pressures, and potential travel demand volatility. Analyst sentiment is mixed with 44% buy ratings, but technical indicators suggest near-term bearish pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
